We track ALCLS.PA stock ahead of Cellectis S.A.’s scheduled earnings on 19 Mar 2026. The share trades intraday at €3.21 (+1.75%), range €3.08–€3.24, with volume 82,140 versus average 263,794. Investors will watch clinical updates and cash runway commentary; biotech catalysts usually move price sharply on results or guidance. We summarise the near-term setup, valuation, technicals, and model-driven forecasts to frame trading and investment decisions.
Market snapshot: intraday moves for ALCLS.PA stock
ALCLS.PA stock is trading on EURONEXT in Europe at €3.21 with a day high of €3.24 and low of €3.08. The stock is up +1.75% intraday but volume is below the 50-day average at 82,140 shares. The 50-day average price is €3.43 and the 200-day average is €2.94, showing mixed momentum against the long-term trend.
Earnings preview and catalysts for ALCLS.PA stock
Earnings are due 19 Mar 2026 and the market will focus on cash burn, R&D milestones and trial readouts. Cellectis is a clinical-stage biotechnology company; clinical updates on UCART and ALLO programmes are primary near-term catalysts. Expect commentary on partnerships and any changes to timelines; those items historically trigger multi‑percent intraday moves.
Valuation and financials: what the numbers say about ALCLS.PA stock
Cellectis reports EPS -0.28 and a negative PE of -11.07, reflecting losses as it scales clinical programs. Price to sales is 3.43, price to book is 3.56, and market cap is about €224.31M. The current ratio is 1.49 and debt to equity is 0.92, showing moderate leverage for the biotech sector. These metrics imply growth expectations priced into the stock despite operating losses.
Technical view and trading setup for ALCLS.PA stock
Technicals show RSI 43.64 and MACD near neutral, suggesting no strong trend intraday. Bollinger middle band sits at €3.37 and ATR is €0.23, so watch €3.13–€3.60 band for breakouts. On low volume, large moves may lack follow-through; traders should weigh the upcoming earnings announcement for volatility.
Meyka AI grade and model forecast for ALCLS.PA stock
Meyka AI rates ALCLS.PA with a score out of 100: 69.06 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €3.30, quarterly €4.06, and yearly €5.60. Compared with the current €3.21, the model implies a near-term upside of 2.97% (monthly), 26.69% (quarterly) and 74.69% (yearly). Forecasts are model-based projections and not guarantees.
Risks and opportunities in the ALCLS.PA stock story
Key risks include trial failures, delayed readouts, and higher-than-expected cash burn. CompanyRating data shows a D+ score and a strong sell signal from one third‑party model dated 16 Mar 2026, which reflects valuation caution. Opportunities are clinical milestones, licensing deals, or positive guidance that could re-rate the stock quickly, given current low float and event sensitivity.
Final Thoughts
ALCLS.PA stock trades at €3.21 with earnings due 19 Mar 2026, making this an event-driven position for traders and investors. Near term, watch clinical commentary, cash runway and any programme updates that could reshape expectations. Our valuation read shows price-to-sales 3.43 and negative EPS, while technicals show neutral momentum and below-average volume. Meyka AI’s model projects a €5.60 price in 12 months, implying +74.69% from today’s €3.21; monthly and quarterly forecasts imply smaller upside. Use earnings as a catalyst, size positions for volatility, and consider the company’s debt to equity 0.92 and current ratio 1.49 when assessing risk. For full company detail visit the Cellectis website and our ALCLS.PA page on Meyka for live updates and tools Meyka ALCLS.PA page. Forecasts and grades are model outputs and are not investment guarantees.
FAQs
When does Cellectis (ALCLS.PA) report earnings?
Cellectis S.A. is scheduled to report on 19 Mar 2026. Expect updates on cash runway, R&D spending, and clinical programme timelines that typically move the stock intraday.
What is Meyka AI’s short-term forecast for ALCLS.PA stock?
Meyka AI’s forecast model gives a monthly target of €3.30, a quarterly target of €4.06, and a 12‑month target of €5.60, with model-based caveats and no guarantees.
How risky is ALCLS.PA stock ahead of earnings?
Risk is high; the company is clinical-stage with negative EPS and event-driven volatility. Key risks are trial setbacks or cash-burn surprises, while positive readouts can sharply re-rate the stock.
What valuation metrics should investors watch for ALCLS.PA stock?
Watch EPS -0.28, price-to-sales 3.43, price-to-book 3.56, current ratio 1.49, and debt to equity 0.92 for a snapshot of valuation and balance-sheet stress.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)